Substance use and opioid use treatment developer Pear Therapeutics announced that it closed an $80 million Series D financing round.
Existing investors Temasek, 5AM Ventures, Arboretum Ventures, JAZZ Venture Partners, Novartis, CrimsoNox and EDBI contributed, as did new investors Forth Management, Pilot House, Sarissa Capital, Shanda Group, and QUAD Investment Management, according to a news release.
Get the full story at our sister site, Drug Delivery Business News.